Metabolic dysfunction-associated steatotic liver disease (MASLD) affects a significant proportion of the global population, with a subset progressing to advanced fibrosis carrying risks of portal hypertension and hepatocellular carcinoma. Non-invasive tests (NITs) including liver stiffness measurement (LSM), FIB-4, NAFLD Fibrosis Score (NFS), and APRI are increasingly used for fibrosis assessment, yet their diagnostic accuracy varies across populations and phenotypes, including lean MASLD